Close up of a clear drug capsule filled with orange beads on a navy background

Erasca ERAS-0015 Posts 44% Response Rate in Pancreatic Cancer

Table of Contents

Erasca’s ERAS-0015 posted a 44% confirmed response rate in pretreated KRAS pancreatic cancer, 69% in G12D and G12V. Here is how it stacks up against Rasonque.

Last updated: November 22, 2026

Erasca reported Phase 1 AURORAS-1 data on November 20 for ERAS-0015, an oral pan RAS molecular glue. At 32 mg daily, 44% of 25 pretreated KRAS G12X pancreatic cancer patients had a confirmed response, with no discontinuations for side effects. Durability data were not disclosed.

Scope: what Erasca disclosed on November 20, how it compares with Revolution Medicines’ approved Rasonque (daraxonrasib), and what has to come next for ERAS-0015 to become a real challenger.

What did Erasca report for ERAS-0015?

Erasca reported confirmed responses across pancreatic, lung and biliary cancers in a 122 patient monotherapy dataset, with the cleanest numbers at the 32 mg once daily dose. The pancreatic cohort is heavily pretreated, and the release gives no progression free survival or duration of response.

The company presented the data at a virtual investor event at 8:00 am ET on Friday, November 20. Erasca describes ERAS-0015 as an investigational oral pan RAS molecular glue designed to inhibit RAS signaling, including RAS wild type variants that the company says may contribute to resistance against mutant selective drugs. The monotherapy data cutoff was September 1, 2026.

The 122 monotherapy patients were dosed at 16 to 32 mg once daily, which Erasca calls the pharmacologically active range. The headline results at 32 mg:

  • Pancreatic cancer, second line or later, KRAS G12X: 44% confirmed objective response rate (n=25). Of these patients, 84% were treated in the third line or later and 44% carried G12R mutations.
  • G12D and G12V pancreatic cancer combined: 69% (n=13), with 77% in the third line or later. By mutation, G12D was 63% (n=8) and G12V was 80% (n=5).
  • Non small cell lung cancer after immunotherapy and platinum: 60% at 32 mg (n=5) and 58% across 16 to 32 mg (n=12).
  • Biliary tract cancer, first line or later: 75% (n=4).

Erasca said all 11 pancreatic responders and 6 of 11 patients with stable disease were still on treatment at cutoff. In colorectal cancer with panitumumab, it reported two ongoing confirmed partial responses and one unconfirmed response among four patients at 16 mg.

How safe is ERAS-0015 so far?

Erasca reported no dose limiting toxicities on monotherapy and no discontinuations for treatment related side effects in the 54 patient 32 mg cohort. The release does not give grade 3 or higher rates or individual side effect percentages, which is the biggest gap in the disclosure.

In the 32 mg cohort, 13.0% of patients had a dose interruption and 16.7% had a dose reduction, with a median relative dose intensity of 100%. Erasca described treatment related events as mostly low grade. One previously disclosed death remains on the record: in April 2026 a patient on 24 mg developed grade 3 pneumonitis that progressed to grade 5 after the patient withdrew supportive care. The company says there have been no further grade 5 treatment related events.

How does ERAS-0015 compare with Rasonque?

Rasonque is already approved on randomized survival data, while ERAS-0015 has small single arm response data. The response rates look higher for ERAS-0015 in G12D and G12V, but no head to head data exist and the populations and endpoints differ.

FDA approved Rasonque on August 26, 2026 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, or who are not candidates for multiagent therapy. The approval rested on RASolute 302 (NCT06625320), a 500 patient randomized trial against chemotherapy.

Measure ERAS-0015 (Erasca) Rasonque (Revolution Medicines)
Status Phase 1 (AURORAS-1), Fast Track in metastatic pancreatic adenocarcinoma FDA approved August 26, 2026
Dose 32 mg once daily (16 to 32 mg active range) 300 mg once daily
Pancreatic evidence Single arm, n=25 at 32 mg, 84% third line or later Randomized vs chemotherapy, n=500
Response rate 44% confirmed overall; 69% G12D and G12V 30% vs 11% for chemotherapy
Survival Not reported Median OS 13.2 vs 6.7 months, HR 0.40
Progression free survival Not reported Median 7.2 vs 3.6 months, HR 0.49
Discontinuation for side effects 0% at 32 mg (n=54) Most common effects per FDA: rash, diarrhea, stomatitis, nausea, fatigue
First line Phase 3 planned 1H 2027 RASolute 303 ongoing; separately, 60.7% response and 12.8 month median PFS with gemcitabine and nab paclitaxel in a 61 patient Phase 1/2 cohort

BioPharma Dive reported that Rasonque’s earlier data in a similar pretreated pancreatic population showed response rates of 32% overall, 24% in G12D and 50% in G12V, and that frequent rashes have been part of its profile. That is the comparison BioPharma Dive drew. It is a cross trial comparison, and BioPharma Dive itself flagged that such comparisons are error prone.

Our read: ERAS-0015’s best case is the mutation split. G12D and G12V make up about two thirds of KRAS mutated pancreatic cancer, according to BioPharma Dive, and G12D is where Rasonque’s response rate has looked softest. A 63% response in eight G12D patients is a signal, not a finding. If it holds at 30 to 50 patients with durable responses, Erasca has a niche Rasonque may struggle to defend. If it regresses toward 40%, the drug has to win on tolerability alone.

What did analysts say about the data?

Views split between real threat and no clear differentiation. All three quotes below come from BioPharma Dive’s November 20 report, not from our own interviews.

  • Asthika Goonewardene of Leerink saw “opportunities to carve out niches that Rasonque may not be able to access.”
  • Leonid Timashev of RBC said ERAS-0015 “could be a formidable competitor in the future.”
  • Tyler Van Buren of TD Cowen said the data “fail to meaningfully differentiate from Rasonque,” and noted oncologists are getting better at managing Rasonque’s side effects.

What is Erasca planning next?

Erasca is moving ERAS-0015 into pivotal work in 2027 across pancreatic and lung cancer, backed by $947.8 million in cash at September 30. The release does not name comparators for any of the planned trials.

  • A potentially registration enabling trial in second line or later RAS mutant lung cancer, starting in the first half of 2027.
  • A Phase 3 in first line pancreatic cancer, which Erasca says it has accelerated to the first half of 2027. Its November 12 third quarter release said only “in 2027.”
  • A Phase 3 in first line RAS mutant lung cancer, starting between the second half of 2027 and the first half of 2028.
  • Combination data in 2027. The gemcitabine and nab paclitaxel combination has cleared 16 mg without dose limiting toxicities (cutoff October 14) and is dosing 24 mg. The pembrolizumab combination has cleared 32 mg.

Erasca also gave a first look at ERAS-4001, a pan KRAS inhibitor in the BOREALIS-1 trial, describing mostly low grade side effects and preliminary activity without numbers. It plans to test ERAS-4001 with ERAS-0015 starting in 2027.

Our framework: five things that would make ERAS-0015 a real challenger

  1. Durability. Duration of response and progression free survival in the 32 mg pancreatic cohort. Rasonque’s bar from RASolute 302 is a 7.2 month median PFS in second line.
  2. Grade 3 and higher rates. Zero discontinuations is encouraging, but tolerability claims need full severity tables.
  3. Bigger G12D numbers. The differentiation story rests on 8 patients.
  4. G12R and wild type activity. 44% of the pancreatic cohort carried G12R, so subgroup results there matter for the pan RAS claim.
  5. The first line comparator. If Rasonque wins RASolute 303 first, Erasca’s first line Phase 3 may have to beat a RAS inhibitor regimen, not chemotherapy alone.

What to watch next

Watch for a medical meeting presentation with durability and full safety tables, the first line pancreatic Phase 3 design and comparator, Rasonque’s RASolute 303 readout, and whether rival pan RAS and KRAS programs show up with clean G12D data. Alterome reported pan KRAS data the same day, with a 31% response rate in colorectal cancer alongside cetuximab, according to BioPharma Dive.

Frequently asked questions

What is ERAS-0015?

ERAS-0015 is Erasca’s investigational oral pan RAS molecular glue, designed to inhibit RAS signaling across mutant and wild type RAS. It is in the Phase 1 AURORAS-1 trial and has FDA Fast Track designation in metastatic pancreatic adenocarcinoma.

What response rate did ERAS-0015 show in pancreatic cancer?

At 32 mg daily, 44% of 25 pretreated KRAS G12X pancreatic cancer patients had a confirmed response. In patients with G12D or G12V mutations, the confirmed response rate was 69% (n=13).

Is ERAS-0015 better than Rasonque?

Nobody can say yet. Rasonque has randomized survival data and FDA approval. ERAS-0015 has small single arm response data with no durability disclosed. Cross trial comparisons are unreliable.

What side effects did ERAS-0015 cause?

Erasca reported mostly low grade events, no dose limiting toxicities, and no discontinuations at 32 mg. One patient died in April 2026 after pneumonitis on 24 mg. Grade 3 and higher rates were not disclosed.

When will ERAS-0015 start Phase 3?

Erasca plans a first line pancreatic cancer Phase 3 in the first half of 2027 and a first line lung cancer Phase 3 between late 2027 and early 2028.

What is Rasonque approved for?

FDA approved Rasonque (daraxonrasib) on August 26, 2026 for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, or who cannot receive multiagent therapy.

What is a pan RAS inhibitor?

A pan RAS inhibitor is designed to block many RAS variants at once rather than a single mutation like KRAS G12C. That matters in pancreatic cancer, where several KRAS mutations, including G12D, G12V and G12R, are common.

How much cash does Erasca have?

Erasca reported $947.8 million in cash at September 30, 2026, after raising about $632.5 million in gross proceeds in July 2026.

What is ERAS-4001?

ERAS-4001 is Erasca’s pan KRAS inhibitor in the BOREALIS-1 trial. Erasca reported mostly low grade side effects and preliminary activity without figures, and plans to combine it with ERAS-0015 in 2027.

Sources

Related coverage

Get the daily briefing: subscribe to BioMed Nexus.

Featured Articles

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters